Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.

NCT07682025 | Enrolling By Invitation

• 1 other identifier: EDGE 183954
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR). Study aims to help tailor patients' treatments and improve outcomes by: \[i\] studying imaging biomarkers of PVR, and \[ii\] develop AI models for PVR detection. Inclusion:

• Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1.
• Patients with 'simple' retinal detachment without PVR recruited to a PhD study. Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.

Conditions

Proliferative Vitreoretinopathy

Outcome Measures

Primary Outcomes (1)

• To study multimodal imaging biomarkers of PVR.

  Use multimodal imaging namely widefield Optos, Widefield OCT, OCT macula, OCT disc, OCT EDI and OCTA to describe biomarkers of PVR.

  Preoperative biomarkers of PVR on cases with established PVR Post-operative biomarkers of PVR on cases that develop PVR in the first 3 months.

Secondary Outcomes (1)

• To develop deep learning AI models for PVR detection in retinal detachment.

  Post-operative 3 months

Study Arms (2)

Rhegmatogenous retinal detachment without proliferative vitreoretinopathy

Rhegmatogenous retinal detachment without proliferative vitreoretinopathy at the time of their primary surgery

Rhegmatogenous retinal detachment with proliferative vitreoretinopathy

Rhegmatogenous retinal detachment with proliferative vitreoretinopathy at the time of their primary surgery or post-operatively with recurrent retinal detachment.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

MORPH-1 - PVR detachments Cohort-NHS - primary RRD without PVR requiring PPV with PVD.

You may qualify if:

• MORPH-1 and Cohort-NHS study imaging

You may not qualify if:

• Participants from above studies who have not consented for image analysis and AI related analysis.

Sponsors & Collaborators

• University College, London: lead

Study Sites (1)

University College London

London, United Kingdom

Location

MeSH Terms

Conditions

Vitreoretinopathy, Proliferative

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases

Study Officials

• James Bainbridge

  University College, London

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2026
• First Posted: July 2, 2026
• Study Start (Estimated): October 12, 2026
• Primary Completion (Estimated): October 15, 2027
• Study Completion (Estimated): October 15, 2027
• Last Updated: July 2, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)